Home LiteratureArticle Details
PMID: 16699001 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Journal of virology ·Vol. 80 ·No. 11 ·2006-06-00 ·Pages 5211-8

Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA

Abstract

Information about neutralizing antibody responses in subtype C-infected individuals is limited, even though this viral subtype causes the majority of AIDS cases worldwide. Here we compared the course and magnitude of the autologous neutralizing antibody (NAb) response against viral envelope (Env) glycoproteins present during acute and early infection with subtypes B and C human immunodeficiency virus type 1 (HIV-1). NAb responses were evaluated in 6 subtype B-infected and 11 subtype C-infected subjects over a mean evaluation period of 25 months using a pseudovirus reporter gene assay. All subjects in the C cohort were infected through heterosexual contact, while five of the six subjects in the B cohort were infected via male-to-male contact. The kinetics and magnitude of the NAb responses varied among subjects in the B and C cohorts; however, the median 50% inhibitory concentration (IC(50) titer) reached by antibody in the plasma of subtype C-infected subjects, overall, was 3.5-fold higher than in the subtype B-infected subjects (P = 0.06). The higher titers of NAbs in the C cohort were associated with viruses having significantly shorter amino acid length (P = 0.002) in the V1 to V4 region of the surface Env glycoprotein, gp120, compared to the B cohort. Despite the potency of the autologous subtype C NAb response, it was not directed against cross-neutralizing epitopes. These data demonstrate that subtype C Envs elicit a potent yet restricted NAb response early in infection that frequently reaches IC(50) titers in excess of 1:1,000 and suggest that clade-specific differences may exist in Env immunogenicity or susceptibility to neutralization.

MeSH Terms
Acquired Immunodeficiency Syndrome/immunology Autoantigens/metabolism Cohort Studies Gene Products, env/chemistry,genetics,immunology HIV Antibodies/blood HIV-1/classification,immunology Humans Neutralization Tests
Chemicals
Autoantigens Gene Products, env HIV Antibodies
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Li Bing
Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA.
Decker Julie M
Johnson Roy W
Bibollet-Ruche Frederic
Wei Xiping
Mulenga Joseph
Allen Susan
Hunter Eric
Hahn Beatrice H
Shaw George M
Blackwell Jerry L
Derdeyn Cynthia A
References (27)
27 references, click to expand
  1. Diversity considerations in HIV-1 vaccine selection.
    Science. 2002 Jun 28;296(5577):2354-60 PMID: 12089434
  2. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18514-9 PMID: 16339909
  3. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Science. 2004 Mar 26;303(5666):2019-22 PMID: 15044802
  4. Perils at mucosal front lines for HIV and SIV and their hosts.
    Nat Rev Immunol. 2005 Oct;5(10):783-92 PMID: 16200081
  5. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    J Infect Dis. 1999 May;179(5):1264-7 PMID: 10191234
  6. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.
    J Virol. 2005 May;79(10):6523-7 PMID: 15858036
  7. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    AIDS. 1990 Feb;4(2):107-12 PMID: 2328092
  8. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    J Virol. 2004 Dec;78(23):13232-52 PMID: 15542675
  9. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    J Virol. 2002 Mar;76(5):2233-44 PMID: 11836401
  10. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection.
    J Virol. 2005 Oct;79(19):12164-72 PMID: 16160143
  11. Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
    J Exp Med. 2005 May 2;201(9):1407-19 PMID: 15867093
  12. Real-time PCR quantitation of subtype C HIV DNA in a Zambian discordant couple cohort.
    AIDS Res Hum Retroviruses. 2006 May;22(5):438-44 PMID: 16706621
  13. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
    Science. 1996 May 24;272(5265):1167-70 PMID: 8638160
  14. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa.
    J Virol. 2005 May;79(9):5762-73 PMID: 15827191
  15. Immunodeficiency virus exploitation of dendritic cells in the early steps of infection.
    J Leukoc Biol. 2003 Nov;74(5):683-90 PMID: 12960236
  16. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    J Virol. 2004 Mar;78(5):2394-404 PMID: 14963135
  17. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.
    J Virol. 2005 May;79(10):6528-31 PMID: 15858037
  18. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 PMID: 12644702
  19. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells.
    Nat Med. 2002 Feb;8(2):150-6 PMID: 11821899
  20. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8 PMID: 15588347
  21. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
    Glycobiology. 2004 Dec;14(12):1229-46 PMID: 15175256
  22. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.
    Science. 1990 Aug 24;249(4971):932-5 PMID: 2392685
  23. Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia.
    J Virol. 2002 Jan;76(1):397-405 PMID: 11739704
  24. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  25. Macrophage HIV-1 infection and the gastrointestinal tract reservoir.
    J Leukoc Biol. 2003 Nov;74(5):642-9 PMID: 12960227
  26. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
    J Acquir Immune Defic Syndr (1988). 1992;5(3):303-7 PMID: 1740756
  27. Chemokine receptor expression on mucosal dendritic cells from the endocervix of healthy women.
    J Infect Dis. 2004 Jul 15;190(2):246-50 PMID: 15216457
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2006-06-00
Pages
5211-8
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1472127
Subset
IM
Grants
NIAID NIH HHS · P30 AI027767 · United States
NIAID NIH HHS · R01 AI 51231 · United States
NIAID NIH HHS · R01 AI051231 · United States
NIAID NIH HHS · R01 AI 58706 · United States
NIAID NIH HHS · P30 AI 27767 · United States
NIAID NIH HHS · R01 AI058706 · United States
NIAID NIH HHS · U01 AI041530 · United States
NIAID NIH HHS · U01 AI 41530 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com